Updated on 2025/07/02

All information, except for affiliations, is reprinted from the information registered on researchmap.

写真a

 
Yoshimi Ishii
 
Organization
YCU Medical Center Medical Center Clean Room Assistant Professor
Title
Assistant Professor
Homepage
http://www.yokohama-cu.ac.jp/urahp/section/blood/index.html
Profile
日本内科学会認定内科医、総合内科専門医。日本血液学会血液専門医取得しています。
External link

Degree

  • 博士（医学） ( 横浜市立大学 )

Research Interests

  • 血液内科学

Research Areas

  • Life Science / Hematology and medical oncology

Papers

  • Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation.

    Jun Nukui, Takayoshi Tachibana, Takuya Miyazaki, Masatsugu Tanaka, Kenji Matsumoto, Yoshimi Ishii, Ayumi Numata, Yuki Nakajima, Ayako Matsumura, Taisei Suzuki, Akihiko Izumi, Natsuki Hirose, Koji Yamamoto, Maki Hagihara, Shin Fujisawa, Heiwa Kanamori, Hideaki Nakajima

    International journal of hematology   119 ( 1 )   62 - 70   2024.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The clinical implications of recipient bone marrow nucleated cell count (NCC) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unknown. We conducted a multicenter retrospective study to evaluate the clinical significance of bone marrow NCC prior to allo-HSCT in patients with acute lymphoblastic leukemia. Patients who were in remission and underwent the initial allo-HSCT were included and stratified into high- and low-NCC groups using an NCC of 10 × 104/µL as the cut-off. The 3-year overall survival (OS), non-relapse mortality (NRM), and relapse rates for the high- and low-NCC groups were 51.2 vs. 84.5% (p < 0.001), 27.5 vs. 6.5% (p < 0.001), and 31.1 vs. 24.4% (p = 0.322), respectively. The high-NCC group had significantly poorer OS and higher NRM when compared with the low-NCC group. In summary, high recipient bone marrow NCC is associated with higher NRM and lower OS following allo-HSCT.

    DOI： 10.1007/s12185-023-03688-7

    PubMed

    researchmap

  • Clinical impact of cigarette smoking on the outcomes of allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. International journal

    Takuma Ohashi, Jun Aoki, Taiki Ando, Yasufumi Ishiyama, Yoshimi Ishii, Kazuho Miyashita, Yuki Nakajima, Takayoshi Tachibana, Maki Hagihara, Kenji Matsumoto, Masatsugu Tanaka, Heiwa Kanamori, Shin Fujisawa, Hideaki Nakajima

    Bone marrow transplantation   57 ( 7 )   1124 - 1132   2022.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Smoking is associated with a high risk for different diseases including respiratory tract infections in immunocompetent patients. However, data about the effects of cigarette smoking on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are limited. Therefore, we retrospectively investigated 608 patients aged ≥20 years with hematological disorders who received their first allo-HSCT at our group of hospitals between 2000 and 2015, and evaluated the impact of cigarette smoking before allo-HSCT on clinical outcomes by dividing patients into two groups according to the Brinkman index (BI) (nonsmokers or light smokers [BI: 0-500] and heavy smokers [BI: ≥ 500]). Multivariate analyses showed that heavy smoking was associated with a high 5-year cumulative incidence of chronic graft-versus-host disease (cGVHD) (hazard ratio [HR]: 1.73, 95% confidence interval [CI]: 1.15-2.61, p < 0.01). The 5-year overall survival (HR: 1.16, 95% CI: 0.86-1.58, p = 0.33) and disease-free survival (HR: 1.12, 95% CI: 0.83-1.52, p = 0.45) were similar between the two groups. Hence, cigarette smoking is correlated with cGVHD, although prospective studies must be conducted to further verify this result.

    DOI： 10.1038/s41409-022-01678-7

    PubMed

    researchmap

  • Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study. International journal

    Hiroyuki Takahashi, Rika Sakai, Takayuki Sakuma, Ayako Matsumura, Kazuho Miyashita, Yoshimi Ishii, Yuki Nakajima, Ayumi Numata, Yukako Hattori, Takuya Miyazaki, Chizuko Hashimoto, Hideyuki Koharazawa, Sachiya Takemura, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Hideaki Nakajima

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion   37 ( 1 )   60 - 66   2021.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We performed a retrospective analysis of DLBCL with breast involvement to compare the prognosis of primary breast lymphoma (PBL) to secondary breast lymphoma (SBL; especially in limited stage cases). We retrospectively reviewed records of 25 diffuse large B-cell lymphoma (DLBCL) patients with breast involvement who received chemotherapy between January 2000 and August 2012. We compared clinical features and prognosis among patients with PBL (n = 11), limited stage SBL (LSBL; n = 6), and advanced stage SBL (ASBL, n = 8). The PBL group had significantly lesser patients with breast tumours (BTs) > 5 cm than the SBL group (P = 0.02). After a median follow-up of 71.3 months, we observed significantly better 5-year overall survival (OS) in the PBL group (90.0%) than in the LSBL (33.3%, P = 0.01) group, but not for progression-free survival (PFS). Patients with BT > 5 cm had worse OS (P = 0.01) and PFS (P = 0.04) than those with BT ≤ 5 cm. PBL had a better prognosis than SBL among limited stage DLBCL.

    DOI： 10.1007/s12288-020-01307-7

    PubMed

    researchmap

  • Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.

    Taiki Ando, Shin Fujisawa, Haruka Teshigawara, Ayako Matsumura, Takayuki Sakuma, Taisei Suzuki, Hiroshi Teranaka, Eriko Ogusa, Yoshimi Ishii, Kazuho Miyashita, Hiroyuki Takahashi, Yuki Nakajima, Takuya Miyazaki, Maki Hagihara, Kenji Matsumoto, Etsuko Yamazaki, Hideaki Nakajima

    International journal of hematology   112 ( 1 )   46 - 56   2020.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We analyzed clinical cutoffs for defining computed tomography (CT) methods for sarcopenia and examined the prognostic value of CT for allogeneic hematopoietic stem cell transplantation (allo-HCST) outcomes of patients with myeloid malignancy. One hundred twenty-five adult patients with acute myeloid leukemia and myelodysplastic syndrome who underwent first allo-HSCT between 2000 and 2017 were included. Sarcopenia was assessed using CT-based skeletal muscle index (SMI) and mean muscle attenuation at L3. A statistical difference in SMI was confirmed between sarcopenia (n = 52) and nonsarcopenia (n = 73) patients. There were no significant correlations of muscularity with age, performance status, or other characteristics of HSCT. After 2 years, overall survival (OS) was 43.5% and 70.1%, disease-free survival was 52.9% and 68.6%, nonrelapse mortality (NRM) was 20.8% and 8.4%, incidence of acute GVHD (≥ grade 2) was 38.8% and 39.1%, that of chronic GVHD was 53.2% and 37.3%, and median duration of hospitalization was 88 days and 74 days (P = 0.026), respectively, in the sarcopenia and nonsarcopenia groups. Multivariate analysis showed that presence of sarcopenia is a novel adverse factor for high NRM and poor OS. Pretransplant CT-defined sarcopenia is correlated with decreased OS, increased NRM, and prolonged hospitalization.

    DOI： 10.1007/s12185-020-02870-5

    PubMed

    researchmap

  • Predictive values of early suppression of tumorigenicity 2 for acute GVHD and transplant-related complications after allogeneic stem cell transplantation: prospective observational study

    Ayako Matsumura, Takuya Miyazaki, Takayoshi Tachibana, Taiki Ando, Megumi Koyama, Satoshi Koyama, Yoshimi Ishii, Hiroyuki Takahashi, Yuki Nakajima, Ayumi Numata, Wataru Yamamoto, Kenji Motohashi, Maki Hagihara, Kenji Matsumoto, Shin Fujisawa, Hideaki Nakajima

    Turkish Journal of Hematology   2019.8

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Galenos Yayinevi  

    DOI： 10.4274/tjh.galenos.2019.2019.0139

    researchmap

  • Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia.

    Taiki Ando, Shin Fujisawa, Haruka Teshigawara, Eriko Ogusa, Yoshimi Ishii, Kazuho Miyashita, Kenji Motohashi, Takuya Miyazaki, Takayoshi Tachibana, Maki Hagihara, Kenji Matsumoto, Masatsugu Tanaka, Chizuko Hashimoto, Hideyuki Koharazawa, Katsumichi Fujimaki, Jun Taguchi, Hiroyuki Fujita, Heiwa Kanamori, Etsuko Yamazaki, Hideaki Nakajima

    International journal of hematology   109 ( 6 )   673 - 683   2019.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We hypothesized that treatment-related weight loss is associated with worse outcomes following HSCT. Overall, 184 patients with AML who underwent induction therapy were classified according to d-BMI (BMI at transplant minus BMI at diagnosis) (kg/m2) as < -2, - 2 to + 2, and > + 2. At 1 year, OS was 67.9% (95% CI, 60.7-74.2), DFS was 64.1% (95% CI, 56.7-70.6), and GRFS was 40.2% (95% CI, 33.1-47.2). For d-BMI groups < - 2, - 2 to + 2, and > + 2, GRFS at 1 year was 16.1% (95% CI, 5.1-31.4), 45.4% (95% CI, 36.4-53.7), and 41.7% (95% CI, 22.2-60.1), respectively (P = 0.0067). Multivariate analysis showed that both worse OS (HR, 1.78; 95% CI, 1.02-3.14; P = 0.007) and GRFS (HR, 2.34; 95% CI, 1.26-4.35; P = 0.007) were associated with reduced BMI (d-BMI < - 2). Treatment-related weight reduction in AML was associated with poor outcome after HSCT.

    DOI： 10.1007/s12185-019-02647-5

    PubMed

    researchmap

  • 初診時白血球の著しい増加を伴わず慢性骨髄性白血病と診断された2例

    白蓋 万葉子, 宮下 和甫, 畠山 まりか, 大橋 卓馬, 徳永 真由美, 青木 淳, 石井 好美, 中嶋 ゆき, 藤澤 信, 中島 秀明

    臨床血液   60 ( 5 )   524 - 524   2019.5

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Primary uterine lymphoma: The Yokohama Cooperative Study Group for Hematology (YACHT) study. International journal

    Yoshimi Ishii, Shin Fujisawa, Taiki Ando, Taisei Suzuki, Yasufumi Ishiyama, Kumiko Kishimoto, Yukako Hattori, Yuki Nakajima, Takuya Miyazaki, Hirotaka Takasaki, Kenji Matsumoto, Hideyuki Koharazawa, Jun Taguchi, Katsumichi Fujimaki, Rika Sakai, Hideaki Nakajima

    Asia-Pacific journal of clinical oncology   14 ( 5 )   e455-e459   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    AIM: Primary malignant lymphomas arising from the female genital tract are very rare, with an incidence rate of 0.5%. Because of its rarity, its clinical characteristics, prognosis and optimal treatment are still unclear. Here, we retrospectively evaluated female patients with uterine lymphoma. METHODS: Between January 2000 and October 2016, 4362 patients were newly diagnosed with malignant lymphoma by the participating institutions of YACHT. Among these 4362 patients, we retrospectively evaluated 14 adult patients with primary uterine lymphoma. RESULTS: The median follow up time was 41 months. The median age at diagnosis was 68 years. Of 14 patients, 10 (72%) were diagnosed with diffuse large B-cell lymphoma. Seven patients presented with vaginal bleeding and three with abdominal pain. Eleven patients (79%) had advanced stages at diagnosis. Three patients (21%) had ovarian involvement and 2 (14%) had vaginal involvement. Induction chemotherapy regimens were R-CHOP in seven patients (50%), CHOP in three (21%) and other regimens in four (29%). Among 14 patients, 12 patients (86%) achieved a complete response and 2 (14%) experienced disease progression. Three patients (21%) showed relapse. Five patients (36%) died because of malignant lymphoma. The 3-year overall survival rate was 57.9%. Soluble interleukin-2 receptor levels > 5000 U/mL, anemia, a bulky mass and the presence of > 1 extranodal sites, B symptom at diagnosis were associated with a poor prognosis. CONCLUSION: Female genital lymphoma is very rare, and further study of more cases is warranted.

    DOI： 10.1111/ajco.13049

    PubMed

    researchmap

  • Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study International journal

    Kenji Matsumoto, Shin Fujisawa, Taiki Ando, Megumi Koyama, Satoshi Koyama, Yoshimi Ishii, Ayumi Numata, Wataru Yamamoto, Kenji Motohashi, Maki Hagihara, Hideaki Nakajima

    Turkish journal of haematology : official journal of Turkish Society of Haematology   35 ( 3 )   181 - 184   2018.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Objective: Useful prognostic biomarkers for diffuse large B-cell lymphoma (DLBCL) patients have been reported. To determine the prognostic value of hemoglobin (Hb) level in DLBCL patients, we performed a retrospective study. Materials and Methods: We evaluated disease outcome, progression-free survival (PFS), overall survival as the endpoint, and clinical and laboratory factors affecting the outcome of 185 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy during 2004-2014. Results: The study group included 121 men and 64 women with a median age of 66 years minimum-maximum: 21-83 years. In univariate analysis, factors independently associated with worse PFS were Eastern Cooperative Oncology Group performance status ≥2, Ann Arbor stage III or IV, anemia with Hb levels of <10 g/dL, and serum albumin of <3.5 g/dL. In multivariate analysis, anemia with Hb levels of <10 g/dL and Ann Arbor stage III or IV were found to be international index-independent prognostic factors (hazard ratio: 2.4; p=0.04). Conclusion: Anemia is an independent prognostic marker of poor outcome in DLBCL patients. Hb can be an easily available prognostic marker for risk stratification in these patients.

    DOI： 10.4274/tjh.2017.0437

    PubMed

    researchmap

  • Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study. International journal

    Takayoshi Tachibana, Taiki Andou, Masatsugu Tanaka, Satomi Ito, Takuya Miyazaki, Yoshimi Ishii, Eriko Ogusa, Hideyuki Koharazawa, Hiroyuki Takahashi, Kenji Motohashi, Jun Aoki, Yuki Nakajima, Kenji Matsumoto, Maki Hagihara, Chizuko Hashimoto, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Shin Fujisawa, Heiwa Kanamori, Hideaki Nakajima

    Clinical lymphoma, myeloma & leukemia   18 ( 6 )   415 - 421   2018.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    PURPOSE: A multicenter retrospective analysis was performed to evaluate the clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia (AML). METHODS: The study cohort included 305 patients who were newly diagnosed with AML from 2000 to 2015 and received standard induction chemotherapy. Transplantation was performed in 168 patients. RESULTS: The median ferritin value was 512 ng/mL (range, 8-9475 ng/mL). Ferritin correlated with lactate dehydrogenase, C-reactive protein, white blood cell count, and blast count, and elevation of ferritin was associated with poor performance status. The median follow-up period was 58 months (range, 4-187 months) among survivors. The high ferritin group (≥ 400 ng/mL) demonstrated inferior event-free survival (EFS) at the 5-year interval (30% vs. 40%; P = .033) compared to the low ferritin group. Multivariate analysis in the high-risk karyotype revealed that high ferritin levels predicted worse EFS (hazard ratio = 2.07; 95% confidence interval, 1.28-3.33; P = .003). CONCLUSION: Elevated ferritin at diagnosis may indicate tumor burden in patients with AML and predict worse EFS in the high-risk group.

    DOI： 10.1016/j.clml.2018.03.009

    PubMed

    researchmap

  • Peripheral Blood Monocyte Count is a Predictor of Successful Peripheral Blood Stem Cell Harvest After Chemo-Mobilization in Patients with Malignant Lymphoma. International journal

    Yoshimi Ishii, Shin Fujisawa, Chika Nigauri, Taiki Ando, Taisei Suzuki, Eriko Ogusa, Kazuho Miyashita, Kenji Motohashi, Hideaki Nakajima

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion   34 ( 2 )   347 - 349   2018.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12288-017-0848-2

    PubMed

    researchmap

  • Body mass index is a prognostic factor in adult patients with acute myeloid leukemia Reviewed

    Taiki Ando, Etsuko Yamazaki, Eriko Ogusa, Yoshimi Ishii, Wataru Yamamoto, Kenji Motohashi, Takayoshi Tachibana, Maki Hagihara, Kenji Matsumoto, Masatsugu Tanaka, Chizuko Hashimoto, Hideyuki Koharazawa, Katsumichi Fujimaki, Jun Taguchi, Hiroyuki Fujita, Heiwa Kanamori, Shin Fujisawa, Hideaki Nakajima

    INTERNATIONAL JOURNAL OF HEMATOLOGY   105 ( 5 )   623 - 630   2017.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-017-2183-7

    Web of Science

    researchmap

  • A case of multiple hepatic lesions associated with methotrexate-associated lymphoproliferative disorder Reviewed

    Ruby Matsumoto, Kazushi Numata, Nobutaka Doba, Koji Hara, Makoto Chuma, Hiroyuki Fukuda, Akito Nozaki, Katsuaki Tanaka, Yoshimi Ishii, Shin Maeda

    JOURNAL OF MEDICAL ULTRASONICS   43 ( 4 )   545 - 551   2016.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s10396-016-0740-y

    Web of Science

    researchmap

  • Favorable prognosis in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia patients following hematopoietic stem cell transplantation. Reviewed

    Numata A, Fujisawa S, Itabashi M, Ishii Y, Yamamoto W, Motohashi K, Matsumoto K, Hagihara M, Nakajima H

    Clinical transplantation   30 ( 5 )   485 - 486   2016.5

    　More details

  • Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis Reviewed

    Wataru Yamamoto, Taiki Andou, Megumi Itabashi, Satoshi Koyama, Yoshimi Ishii, Ayumi Numata, Kenji Motohashi, Maki Hagihara, Kenji Matsumoto, Shin Fujisawa

    INTERNAL MEDICINE   55 ( 13 )   1721 - 1727   2016

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.2169/internalmedicine.55.6094

    Web of Science

    researchmap

  • 後天性血友病Aに対してプレドニゾロン(PSL)とシクロフォスファミド(CPA)併用療法が有効であった1例 Reviewed

    石塚 晃介, 松本 憲二, 本橋 賢治, 石井 好美, 藤澤 信, 長谷川 修

    日本病院総合診療医学会雑誌   8 ( 2 )   19 - 24   2015.6

    　More details

  • Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients Reviewed

    Naoto Tomita, Fumio Kodama, Naoko Tsuyama, Seiji Sakata, Kengo Takeuchi, Daisuke Ishibashi, Satoshi Koyama, Yoshimi Ishii, Wataru Yamamoto, Hirotaka Takasaki, Maki Hagihara, Hideyuki Kuwabara, Masatsugu Tanaka, Chizuko Hashimoto, Etsuko Yamazaki, Hideyuki Koharazawa, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Yoshiaki Ishigatsubo

    HEMATOLOGICAL ONCOLOGY   33 ( 1 )   9 - 14   2015.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/hon.2136

    Web of Science

    PubMed

    researchmap

  • Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study Reviewed

    Wataru Yamamoto, Naoya Nakamura, Naoto Tomita, Kengo Takeuchi, Yoshimi Ishii, Hiroyuki Takahashi, Reina Watanabe, Hirotaka Takasaki, Shigeki Motomura, Shoichi Kobayashi, Tomoyuki Yokose, Yoshiaki Ishigatsubo, Rika Sakai

    LEUKEMIA & LYMPHOMA   55 ( 12 )   2721 - 2727   2014.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3109/10428194.2014.893311

    Web of Science

    PubMed

    researchmap

  • Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation.

    Yoshimi Ishii, Etsuko Yamazaki, Yasufumi Ishiyama, Eri Yamamoto, Yukako Hattori, Maki Hagihara, Naoto Tomita, Yoshiaki Ishigatsubo

    International journal of hematology   98 ( 6 )   723 - 8   2013.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    POEMS syndrome is a monoclonal plasma cell disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) are an effective therapy, but optimal treatment options are still under debate. Bortezomib is an important agent for the treatment of patients with multiple myeloma and has recently been reported as efficacious in the treatment of patients with POEMS syndrome. We present a case of POEMS syndrome in a 33-year-old woman, who was successfully treated with BorDex (bortezomib and dexamethasone) combined with radiotherapy, and followed by ASCT. She was diagnosed with POEMS syndrome with a localized plasmacytoma of bone 5 months after her initial symptoms of heart failure. Her Eastern Cooperative Oncology Group (ECOG) performance status was 4. She was first administered BorDex therapy, which was subsequently combined with radiotherapy. Her general condition including heart failure dramatically improved after four cycles of BorDex therapy and radiation, resulting in partial response. After chemoradiotherapy, HDT and ASCT were performed. After treatment, she was able to walk unassisted and her plasma endothelial growth factor (VEGF) level decreased. She did not experience neurotoxicity induced by bortezomib. Bortezomib was well tolerated and we suggest that BorDex therapy followed by HDT and ASCT may be an effective therapy for POEMS syndrome.

    DOI： 10.1007/s12185-013-1456-z

    PubMed

    researchmap

  • Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone Reviewed

    Reina Watanabe, Naoto Tomita, Kumiko Kishimoto, Satoshi Koyama, Eriko Ogusa, Yoshimi Ishii, Kazuho Miyashita, Shiro Matsuura, Shin Fujisawa, Yukako Hattori, Hirotaka Takasaki, Atsuko Fujita, Rika Ohshima, Hideyuki Kuwabara, Chizuko Hashimoto, Katsumichi Fujimaki, Rika Sakai, Yoshiaki Ishigatsubo

    LEUKEMIA RESEARCH   37 ( 10 )   1208 - 1212   2013.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.leukres.2013.07.015

    Web of Science

    researchmap

  • Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

    TOMITA Naoto, TAKASAKI Hirotaka, FUJISAWA SHIN, MIYASHITA Kazuho, OGUSA Eriko, KISHIMOTO Kumiko, MATSUURA Shiro, SAKAI Rika, KOHARAZAWA Hideyuki, YAMAMOTO Wataru, FUJIMAKI Katsumichi, FUJITA Hiroyuki, ISHII Yoshimi, TAGUCHI Jun, KUWABARA Hideyuki, MOTOMURA Shigeki, ISHIGATSUBO Yoshiaki

    The journal of the Japanese Society of Lymphoreticular Tissue research   53 ( 2 )   121 - 125   2013.8

    　More details

    Language：English   Publisher：The Japanese Society for Lymphoreticular Tissue Research  

    The introduction of rituximab (R) has measurably improved the outcome of patients with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). To evaluate the outcome of patients with FL and DLBCL under R plus CHOP therapy, we performed a retrospective analysis in Yokohama City University Hematology Group in Japan. Five hundred and twenty-six patients (158, FL ; 368, DLBCL) were scheduled to undergo primary therapy with 6 cycles of full-dose R-CHOP therapy with curative intent. The median observation periods in livingpatients with FL and DLBCL were 45 months and 43 months, respectively. The complete response, 5-year progression-free survival (PFS), and 5-year overall survival (OS) rates were 86%, 50%, and 92% in the FL group, and 89%, 72%, and 80% in the DLBCL group, respectively. Although PFS was significantly better in the DLBCL group than in the FL group, OS was significantly better in FL patients. We also found that the OS and PFS of grade 3 FL patients were not statistically different from those with grade 1-2. These findings indicate that all grades of FL should be categorized simply as "FL" with regard to R-CHOP therapy. Our results also demonstrate the incurability of FL (grade 1-3B), even with R-CHOP therapy. [<I>J Clin Exp Hematop 53(2) : 121-125, 2013</I>]

    DOI： 10.3960/jslrt.53.121

    CiNii Books

    researchmap

    Other Link： http://search.jamas.or.jp/link/ui/2014164063

  • Upfront Autologous Stem Cell Transplantation for Untreated High-Risk Diffuse Large B-Cell Lymphoma in Patients Up to 60 Years of Age Reviewed

    Hirotaka Takasaki, Chizuko Hashimoto, Atsuko Fujita, Kenji Matsumoto, Jun Taguchi, Hideyuki Kuwabara, Etsuko Yamazaki, Hideyuki Koharazawa, Hiroyuki Fujita, Shin Fujisawa, Yoshimi Ishii, Wataru Yamamoto, Shigeki Motomura, Naoto Tomita, Yoshiaki Ishigatsubo, Rika Sakai

    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA   13 ( 4 )   404 - 409   2013.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.clml.2013.03.003

    Web of Science

    researchmap

  • Clinicopathological analysis of mediastinal large B-cell lymphoma and classical Hodgkin lymphoma of the mediastinum. International journal

    Wataru Yamamoto, Naoya Nakamura, Naoto Tomita, Yoshimi Ishii, Hirotaka Takasaki, Chizuko Hashimoto, Shigeki Motomura, Etsuko Yamazaki, Rika Ohshima, Ayumi Numata, Yoshiaki Ishigatsubo, Rika Sakai

    Leukemia & lymphoma   54 ( 5 )   967 - 72   2013.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Primary mediastinal (thymic) large B-cell lymphoma (PMLBCL) and nodular sclerosing classical Hodgkin lymphoma (NSCHL) are the major histological types of lymphoma affecting the mediastinum. We reviewed 27 patients with PMLBCL and 14 patients with NSCHL. A poor performance status, high serum lactate dehydrogenase level and strong positivity for PAX5 were all significantly more common in patients with PMLBCL than in those with NSCHL. Severe fibrosis was frequent in NSCHL, but not in PMLBCL. PDL1 was expressed by 11/25 PMLBCLs (44.0%) vs. 1/9 NSCHLs (11.1%). Expression of BCL6 was significantly more frequent in PDL1-positive PMLBCL than in PDL1-negative PMLBCL, but there were no clinical differences between these two groups. Two patients with PMLBCL with a poor prognosis had CD20(-), CD79a(+), CD15(-), and CD30(-), possibly representing a subtype of mediastinal gray zone lymphoma.

    DOI： 10.3109/10428194.2012.733881

    PubMed

    researchmap

  • Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population

    Eriko Ogusa, Naoto Tomita, Yoshimi Ishii, Hirotaka Takasaki, Yukako Hattori, Chihiro Matsumoto, Yoshiaki Ishigatsubo

    Hematological Oncology   31 ( 1 )   18 - 21   2013.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/hon.2008

    Scopus

    PubMed

    researchmap

  • Twenty-eight cases of relapsed or refractory multiple myeloma treated with lenalidomide

    Yukako Hattori, Katsumichi Fujimaki, Yoshimi Ishii, Satomi Itoh, Rika Ohshima, Maki Hagihara, Kenji Matsumoto, Hideyuki Koharazawa, Chizuko Hashimoto, Rika Sakai, Hiroyuki Fujrra, Hiroshi Haran, Koji Ogawa, Naoto Tomita, Shin Fujisawa, Yoshiaki Ishigatsubo

    Yokohama Medical Journal   64 ( 2 )   39 - 43   2013

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Medical Association of Yokohama City University  

    Scopus

    researchmap

  • Clinical features of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. International journal

    Yoshimi Ishii, Naoto Tomita, Hirotaka Takasaki, Eriko Ogusa, Yukako Hattori, Shiro Matsuura, Chihiro Matsumoto, Sachiya Takemura, Hideyuki Kuwabara, Yoshiaki Ishigatsubo

    Hematological oncology   30 ( 4 )   186 - 9   2012.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We newly diagnosed 131 patients with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue lymphoma between 1998 and 2010. We retrospectively studied 124 patients for whom complete clinical data were available at presentation and who had minimally undergone tumour staging by physical examination, computed tomography (CT), bone marrow aspiration, and biopsy. A slight female predominance (men, 58; women, 66) was observed in the study population; the median age was 67 years. The primary locations at presentation were the stomach (38%), orbita (20%), lung (12%), intestinal tract (8%), thyroid gland (6%), others (14%), and unknown (2%). Seventy per cent of patients had localized disease. Of the 124 patients, 14 (11%) had lymph node involvement, and 5 (4%) had bone marrow involvement. Five (4%) patients had both lung and gastric involvement. The 5-year overall survival rate for the 124 patients was 96.1%. The overall vital prognosis was excellent. Moreover, gastro-intestinal fiberscopic examination is essential, especially in cases with lung involvement at presentation.

    DOI： 10.1002/hon.2006

    PubMed

    researchmap

  • Maximum standard uptake value at the biopsy site during (18)F-fluorodeoxyglucose positron emission tomography does not predict the proliferation potential of tumor cells in extranodal natural killer/t cell lymphoma, nasal type. International journal

    Yoshimi Ishii, Naoto Tomita, Seiji Sakata, Kengo Takeuchi, Ukihide Tateishi, Reina Watanabe, Rika Sakai, Yoshiaki Ishigatsubo

    Acta haematologica   128 ( 2 )   110 - 2   2012

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1159/000338263

    PubMed

    researchmap

▼display all

MISC

▼display all